Effector Selects Lead Cancer Compound, Looks Ahead To Combo Regimens
This article was originally published in The Pink Sheet Daily
Executive Summary
Leading the way in translation regulation, biotech moves its first candidate into clinical development in solid tumors, but plans quick move also into lymphoma.
You may also be interested in...
eFFECTOR Translates $38.6m Into Five Cancer Clinical Trials
The firm's $38.6m in Series C cash will fund additional clinical trials for lead translation regulator eFT508, support the first human trial for eFT226 and advance a third program into preclinical studies.
A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million
Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”